Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
Neuraminidase-1 can cause the removal of terminal sialic acid residues from the cell surface
or serum sialyloconjugates. The level of Neu5Ac was positively related to the activity of
neuraminidase-1. Elevation of Neu5Ac was observed in myocardial ischemia animal model, as
well as patients with coronary artery disease. It is interesting to note that Neu5Ac and its
regulatory enzyme neuraminidase-1 seem to play a key role in triggering myocardial ischemic
injury. Oseltamivir, a structural mimic of sialic acid, was widely used as anti-influenza
drug. It suppressed neuraminidase-1 activity in the heart. Targeting neuraminidase-1 may
represent a new therapeutic intervention for coronary artery disease. This project seeks to
identify whether neuraminidase inhibitor (Oseltamivir) treatment could decrease the
myocardial infarct size in STEMI patients and improve clinical outcomes.